|Bid||5,922.00 x 0|
|Ask||5,925.00 x 0|
|Day's Range||5,825.00 - 5,929.00|
|52 Week Range||5,510.00 - 6,778.00|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||29.69|
|Earnings Date||Jul. 30, 2019|
|Forward Dividend & Yield||1.46 (2.52%)|
|1y Target Est||7,085.56|
Investors who take an interest in Reckitt Benckiser Group plc (LON:RB.) should definitely note that the Chief...
The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.
Reckitt Benckiser's new chief executive promised on Tuesday to step up spending on its brands and improve performance after the British household goods maker cut its full-year sales forecast for a second time. "We are not pleased with where we are and we must consistently deliver," Laxman Narasimhan, who took over from long-time CEO Rakesh Kapoor in September, said on his first call with the investment community. Narasimhan particularly lamented the performance of the firm's Health business, its largest, where a failed product launch, the nearly $17 billion acquisition of Mead Johnson, and a temporary baby milk factory shutdown in the Netherlands, have all caused significant disruption, some lasting to this day.
The maker of Durex condoms and Lysol disinfectant said on Monday that Carr, who has been finance chief at Dutch-American supermarket operator Ahold since 2011, would bring "extensive experience across consumer and retail companies". The appointment of Carr, who worked for Reckitt between 1994 and 2004, is its second big management change this year after replacing long-time chief executive Rakesh Kapoor with PepsiCo executive Laxman Narasimhan as CEO.
The big shareholder groups in Reckitt Benckiser Group plc (LON:RB.) have power over the company. Insiders often own a...
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
The blue-chip index followed Wall Street lower after U.S. President Donald Trump warned China not to wait for the 2020 U.S. presidential election to make a trade deal. Big British banks, such as Barclays and RBS , fell after the BoE said banks would have to tell investors in 2021 if they could be closed down without disrupting financial markets. Corporate earnings were the main drivers behind most of the major stock moves on both UK indexes.
Reckitt Benckiser cut its full-year revenue target after reporting lower than expected sales in its last quarter under long-time chief executive Rakesh Kapoor, hurt by a surprise slowdown in demand for infant formula in China. The Durex condom and Lysol disinfectant maker said on Tuesday it now expected full-year like-for-like sales growth of between 2% and 3%, down from its previous target of 3% to 4%, also blaming a tough market in Europe for its downgrade. Reckitt, which kept its "broadly flat" operating margin target, said slowing birth rates over the past two years and increased competition had led to market share losses for its Enfamil infant nutrition products in China, its biggest market for baby food.
The FTSE 100 shed 0.3%, while the mid-cap FTSE 250 capitalised on a rise in sterling to add 0.1%. The U.S. government scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients. "Overall, we view this outcome as a modest negative for the major pharmaceutical group," JP Morgan analysts wrote, adding that the move had removed a "potential positive catalyst" for the sector.
The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.
(Bloomberg Opinion) -- Reckitt Benckiser Group Plc has appointed Laxman Narasimhan as its new chief executive officer, succeeding Rakesh Kapoor. An outsider should herald a fresh start for a group that was once a superstar, but has more recently become a laggard.Reckitt has eschewed some of the obvious candidates for the role, such as Tesco Plc’s Dave Lewis or Unilever’s Nitin Paranjpe. It has instead chosen Narasimhan, who joins from PepsiCo Inc., where he was global chief commercial officer.He’s an unknown quantity outside of the U.S. He had a career spanning almost 20 years at McKinsey, before moving to Pepsi. While he was well-regarded there, its change of CEO might have left him as one of the senior executives who missed out on the top job and was therefore looking for opportunities outside of the soft drinks maker.And Reckitt has some particular challenges. It has endured a tumultuous few years, following the $16.6 billion acquisition of Mead Johnson in 2017.Narasimhan should at least bring a burst energy to the group. Kapoor was increasingly worn down by Reckitt’s problems.The first task of the incoming leader is to revive sales expansion, which has stalled. He must also complete the integration of Mead Johnson. It did seem as if it was improving, but hit another bump in the road last year, in the form of disruption to a plant in the Netherlands. Not having been involved in the purchase, Narasimhan can take an impartial view on the best way to tackle what increasingly looks like the wrong deal to have done.Narasimhan must both fit in with Reckitt’s culture, and evolve it. It has a particular hard-driving approach, where cost-cutting to bolster margins is at the forefront. That has gone out of fashion with investors, who want a better balance between top line and bottom line growth. The new CEO will have more scope to warn that margins must come down to facilitate the investment needed to turbocharge sales.Kapoor reorganized Reckitt into two divisions: one focused on household products, such as Cillit Bang cleaner, and the other on consumer health treatments including Nurofen painkillers. As well as being CEO, Narasimhan will directly lead the health arm.But the outgoing CEO hadn't yet taken that to its logical conclusion: separating the two units, possibly through a sale of hygiene and home. While Kapoor had earmarked this as a job for mid-2020, it will fall to his successor to complete the task.A split is not a given: new leaders don’t usually like to take an ax to their empires. There is also a question mark over whether Narasimhan can break up the group, even if he wanted to.As my colleague Chris Hughes has argued, this reinvention could be hampered by the aftershocks from the Justice Department’s indictment of Indivior Plc, the pharma business Reckitt spun off back in 2014. The drugmaker faces a $3 billion fine after U.S. prosecutors alleged it lied about the dangers of its opioid addiction treatment.That Narisimhan didn’t have any hand in the Indivior spin off means he has no baggage associated with the original deal, which would impede finding a solution. Having been based in the U.S., he should also have experience of dealing with regulators there.Indeed, this underlines the benefit of appointing an outsider – to both the company and the broader European consumer goods sector – he has much more latitude to take the difficult decisions that Reckitt needs to regain its stellar status.To contact the author of this story: Andrea Felsted at email@example.comTo contact the editor responsible for this story: Jennifer Ryan at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Narasimhan, PepsiCo's global chief commercial officer, is the first external candidate to be appointed as CEO at Reckitt since the maker of Durex condoms, Nurofen tablets and Dettol cleaners was formed in 1999. The 52-year-old takes over as CEO on Sept. 1, replacing Rakesh Kapoor, 60, who has led Reckitt for more than eight years and said in January he would retire this year.
At a meeting with 10 British and U.S. businesses at St James' Palace, the Queen's official residence, May will tell companies such as defense contractor BAE Systems and pharmaceuticals giant GlaxoSmithKline that greater cooperation would boost the two countries' economic partnership. "It is a great partnership, but one I believe we can make greater still," she will say, according to advance extracts from her office.
Reckitt Benckiser is working to resolve both its search for a new chief executive and its position relating to U.S. charges of wrongdoing at a former business, its chairman told investors at its annual general meeting on Thursday. The maker of Lysol cleaners and Durex condoms is "well under way with a comprehensive process" to select a successor to Chief Executive Rakesh Kapoor, Chairman Christopher Sinclair said at the meeting in London. "I'm hopeful that in the not-too-distant future, we'll have something significant to report here," Sinclair said.
LONDON/BEIJING (Reuters) - Nestle plans to launch a new line of baby formula in China this year under an existing brand, targeted at smaller cities, as the world's largest packaged food company tries to lengthen its lead in the world's biggest baby milk market. The new line, discussed exclusively with Reuters, will focus on smaller provincial cities, often in China's western provinces, where greater shipping distances and lower incomes can make some imported brand goods unaffordable, though wealth there is growing. Producers of many consumer staples such as soft drinks and soap had to seek growth in the less-profitable provincial cities years ago, as China's richer eastern markets matured.
Not for Reckitt Benckiser Group Plc, which reported weaker-than-expected first-quarter sales on Thursday. All this means Reckitt will find it a bit harder to achieve its full-year target of 3-4 percent like-for-like sales growth. It may get some help from infant nutrition, where sales growth of 5 percent indicates that the division is recovering from a disruption to baby milk supplies last year.
The FTSE 100 was largely flat on Monday, as oil majors dipped following United States' demand to OPEC for higher production, while online supermarket Ocado slipped after disclosing the cause of the fire at its Andover site earlier this year. Meanwhile, travel groups TUI and Thomas Cook rose over 2 percent after the latter said British holidaymakers are favoring destinations outside the European Union.
The consumer good group’s strategy now looks to be a hostage to U.S. lawyers. Under outgoing CEO Rakesh Kapoor, Reckitt had been simplifying and refocusing its portfolio. This effort was expected to culminate in the division of the business into two separate companies: one focused on household products such as Cillit Bang cleaner and Finish dishwasher tabs, the other on consumer health treatments like Nurofen painkillers and Gaviscon heartburn tablets.
There were many reasons for Kapoor and fellow managers to demerge Indivior Plc in 2014. Reckitt got the demerger away before the competition struck. On Wednesday, litigation risk became a stark reality, hitting Indivior and its former parent hard.
European shares rose slightly on Wednesday as gains across most sectors offset losses among lenders, which were hit by a lack of detail in European Central Bank (ECB) comments after the bank left borrowing costs unchanged. The ECB's decision on rates matched investors' expectations but President Mario Draghi's comments shed very little light on reported plans for a tiered deposit rate and a new round of ultra-cheap bank loans.